Navigation Links
Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimer's Disease at International Conference on Alzheimer's Disease (ICAD)
Date:7/15/2010

cs company; Sylentis, which focuses on researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

About Noscira:

Noscira, which is headquartered in Madrid (Spain), is a biopharmaceutical company which researches and develops innovative drugs for treating and preventing diseases of the nervous system. Since its inception, the company has specialized in Alzheimer's disease. Noscira's search strategy combines a unique, highly-specialized primary screening platform for marine samples and a strong focus on chemical optimization.

The company has two clinical compounds (NP-12 and NP-61) which are well-positioned in the pipeline for treating Alzheimer's disease. It also has a solid pipeline of products in the pre-clinical phases. Noscira is a subsidiary of Grupo Zeltia (Madrid stock exchange: ZEL.MC; Bloomberg: ZEL SM; Reuters: ZEL.MC), Spain's leading biotechnology and chemical company.

About Nypta(R) (Tideglusib) (NP-12):

Overexpression of GSK-3 leads to hyperphosphorylation of the tau protein, an anomaly which occurs in a number of neurodegenerative diseases known collectively as tauopathies, which include Alzheimer's disease (AD), progressive supranuclear palsy (PSP) and Pick disease.

NP-12 is a GSK-3 inhibitor with oral bioavailability and great therapeutic potential as a disease-modifying treatment for Alzheimer's disease. NP-12 is currently undergoing Phase II clinical trials for Alzheimer's disease in the EU.

NP-12, the only GSK-3 inhibito
'/>"/>

SOURCE Group Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 ... ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting clinical ... Under the terms of the collaboration, Foundation Medicine ... component of Foundation Medicine,s FoundationOne® assay at the WuXi ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... , , , , ... The Heart Failure Society of America,s (HFSA) 13th Annual ... in Boston. This three-day meeting -- a forum for heart failure specialists ... trends in research and new developments in the approach to treating patients ...
... , , , ... AMGN ) today announced the presentation of data highlighting ... reduction among women with postmenopausal osteoporosis. The data were presented at ... Research (ASBMR). , , "These data enhance our ...
Cached Medicine Technology:Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench-To-Bedside Approach 2Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench-To-Bedside Approach 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 5Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 6Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 7Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 8Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 9
(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open ... American Institutes for Research (AIR) finds that three out of ... insurance, but 42 percent say they are not likely or ... up for coverage. , The AIR survey found wide gaps ... to calculate correctly how much they owe for a routine ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... Haelle HealthDay Reporter , TUESDAY, ... adult men may lead to increased blood pressure, according to ... similar rise in blood pressure for young adult women or ... adult women drank lightly or moderately, their risk of high ... "This finding parallels studies in older adult men and women," ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... new low cost test for acute pancreatitis that gets results ... at The University of Texas at Austin. The sensor, ... is built with a 12-cent LED light, aluminum foil, gelatin, ... The sensor could help prevent damage from acute pancreatitis, ...
... HealthDay Reporter , MONDAY, April 25 (HealthDay News) ... because it does not adequately protect children and pregnant ... new position paper from the American Academy of Pediatrics ... Act (TSCA) in 1976, tens of thousands of new ...
... the ion selectivity of cation-selective channels and transporters. The ... Journal of General Physiology ( www.jgp.org ). ... introduction, a key tool in most recent studies on ... emphasize the fluid-like features of the selectivity filter and ...
... April 25, 2011 Cancer has a mighty big bag ... defense mechanisms and proliferate. Among those tricks is one that ... of lymphatic vessels into something of a highway to metastasis. ... of therapeutics that will put the brakes on such cancer ...
... April 22, 2011 - Sanofi Pasteur, the vaccines division ... announced today that the U.S. Food and Drug Administration ... its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, ... include a two-dose schedule for infants and children 9 ...
... infections in newborns can lead to serious complications ... pathogens responsible for neonatal infections have changed over ... to at-risk mothers has reduced the incidence of ... A new nationwide, multi-site study aimed at ...
Cached Medicine News:Health News:Self-powered, blood-activated sensor detects pancreatitis quickly and cheaply 2Health News:Pediatricians Urge Better Protection From Chemicals 2Health News:Pediatricians Urge Better Protection From Chemicals 3Health News:Laying bare the not-so-sweet tale of a sugar and its role in the spread of cancer 2Health News:Laying bare the not-so-sweet tale of a sugar and its role in the spread of cancer 3Health News:Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants 2Health News:Streptococci and E. coli continue to put newborns at risk for sepsis 2
... for planned ECCE with peristaltic pump ... irrigation, suction, reflux possible with multi-function ... control all critical functions. You can ... and actual vacuum level indicated by ...
...
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium...
The CGAL gonioscopic contact glass was designed by Roussel and Fankhauser for,laser treatments of the chamber angle. It reduces the laser spot by a factor of 1.5 as compared to a Goldmann Glass....
Medicine Products: